[Treatment of functional changes in arteriosclerotic chronic obliterating peripheral arterial diseases (COPA) and Buerger's and Raynaud's diseases with pharmacological sympathicolysis, with or without indirect surgical treatment].
D000328:Adult; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy* / Q000601:surgery; D001161:Arteriosclerosis / Q000188:drug therapy; D005021:Ethylamines / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005260:Female; D005663:Furans / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use; D011422:Propionates / Q000627:therapeutic use; D011928:Raynaud Disease / Q000188:drug therapy*; D013562:Sympathectomy; D013565:Sympatholytics / Q000627:therapeutic use*; D013919:Thromboangiitis Obliterans / Q000188:drug therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use
D005021:Ethylamines; D005663:Furans; D009281:Naphthalenes; D011422:Propionates; D013565:Sympatholytics; D014665:Vasodilator Agents
Trattamento delle alterazioni funzionali delle arteriopatie obliteranti croniche periferiche (A.O.C.P.) arteriosclerotiche, e tipo Buerger e del morbo di Raynaud mediante simpaticolisi farmacologica, associata o non a terapia chirurgica indiretta.